New insights into the role of ID proteins in breast cancer metastasis: a MET affair by Wee Siang Teo et al.
Teo et al. Breast Cancer Research 2014, 16:305
http://breast-cancer-research.com/content/16/2/305VIEWPOINTNew insights into the role of ID proteins in breast
cancer metastasis: a MET affair
Wee Siang Teo1,2, Radhika Nair1,2 and Alexander Swarbrick1,2*Abstract
The establishment of lethal metastases depends on the
capacity of a small number of cancer cells to regenerate
a tumor after entering a target organ. Stankic and
colleagues have identified a role for the inhibitor of
differentiation protein, ID1, as a critical regulator of
breast cancer stem-like properties and metastatic
colonization. Under the control of tumor growth factor-
beta signaling, ID1 induces mesenchymal-epithelial
transition at the metastatic site by antagonizing the
activity of the basic helix-loop-helix transcription factor
Twist1. This study sheds light on mechanisms that
initiate metastatic outgrowth, and strengthens the
concept that epithelial-mesenchymal plasticity is crucial
at different stages of metastasis.renewal capacity, enrichment in CD44high/CD24low expres-
sion, and an increased tumor-initiating potential by limit-Background
A major focus of metastatic studies is in understanding
the mechanisms by which tumor cells escape the local
environment and colonize distant organs. Emerging
evidence suggests that activation of the epithelial-to-
mesenchymal transition (EMT) program drives metasta-
sis [1] and is associated with a gain of mesenchymal
properties and stem cell-like behavior [2,3]. It has been
proposed that the reversal of EMT, the mesenchymal-to-
epithelial transition (MET), is necessary for efficient
metastatic colonization by allowing re-differentiation of
disseminated tumor cells into an epithelial phenotype re-
quired for proliferation [1]. Although clinical reports
support the concept of transient EMT-MET switches in
metastasis [4], there is only limited experimental evi-
dence for this phenomenon and few insights into the
mechanisms that induce MET in metastatic sites.* Correspondence: a.swarbrick@garvan.org.au
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A recent study from Robert Benezra’s group [5] provides
evidence to support the role of a MET program for
efficient metastatic growth and a mechanism controlling
this process. The authors identified the inhibitor of differ-
entiation protein, ID1, as a critical regulator of breast
tumor-initiating phenotype and metastatic colonization.
ID1 is a helix-loop-helix protein which acts as a dominant
negative regulator of many transcription factors [6]. ID1 is
overexpressed in aggressive triple-negative breast tumors
[7] and is required for the metastasis of breast cancer in
experimental models [8-10]. Using the immortalized hu-
man mammary epithelial cells, Stankic and colleagues [5]
showed that overexpression of ID1 can generate breast
cancer cells with cancer stem cell (CSC)-like properties
and that these cells were characterized by a high self-
ing dilution transplantation assay in vivo. However, during
the process of metastatic colonization, ID1 induces MET
in cells that had previously undergone EMT. Conditional
overexpression of ID1 revealed that ID1 promotes lung
metastasis by inducing MET at the metastatic site through
antagonism of the basic helix-loop-helix transcription
factor Twist1. Interestingly, ID1 did not act in the same
manner in the primary site, where this state is controlled
by the zinc finger protein Snail. Knockdown of ID1 and
ID3 expression in metastasizing cells results in a failure to
initiate MET and dramatically reduces lung colonization,
providing strong evidence that ID proteins are required for
the maintenance and propagation of disseminated tumor
cells. The authors further demonstrated that ID1 expres-
sion is regulated by tumor growth factor-beta (TGF-β) and
that upregulation of ID1 by TGF-β occurs only in dissemi-
nated cancer cells that had initially seeded in a mesenchy-
mal state, suggesting that EMT is a prerequisite for
subsequent ID1-induced MET during lung colonization.. The licensee has exclusive rights to distribute this article, in any medium, for 6
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This study supports the role of phenotypic plasticity in
breast cancer metastasis and, in particular, the necessity of
the acquisition of a MET program at the distant organs for
colonization. The complex context-dependent function of
ID1 allows breast cancer cells to retain their EMT-CSC-
like mesenchymal phenotype during tumor initiation and
metastatic dissemination, and to re-acquire their epithelial
character necessary for lung colonization. Since TGF-β can
derive from both tumor and host tissue stroma [11], this
implies a regulation of the TGF-β-ID1-induced MET plas-
ticity by environmental conditions and contextual signals
and a possible role of ID1 in determining organ tropism.
Interestingly, the authors showed that the CSC-like prop-
erties induced by ID1 are independent of induction of
EMT; this finding is contrary to the notion that CSC
properties are inextricably linked to a mesenchymal state.
This also corroborates recent work by our group [12] and
others [13] that the canonical EMT program is not often
associated with CSC-like properties, and prompts further
investigations to better define the biology and differenti-
ation state of CSCs. Although the authors have used trans-
planted cancer cell lines to illustrate CSC-like properties
and the transient nature of the mesenchymal phenotype
controlled by ID1, evidence for the existence of such CSCs
and plasticity in spontaneously arising tumors in vivo or in
human tumors remains to be determined. Furthermore,
ectopic gene expression of EMT inducers and ID1 may not
provide conclusive evidence of these concepts in a complex
in vivo tumor setting. More evidence can be achieved by
lineage tracing of an EMT-MET phenotype in spontaneous
mouse models of metastatic cancer or inducible loss of
ID1 function.
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